Developing Cell and Gene Therapies
for Rare Genetic Diseases and Cancer
Leveraging Innovations in the
US and Fast-growing Market in Asia
Celgenyx is a biotechnology company dedicated to the acquisition, development and commercialization of value-added, next-generation cell and gene therapies for rare genetic diseases and cancer.
The Company is founded by a group of scientists, clinicians, and entrepreneurs with hand-on experience and expertise on drug development and commercialization for global markets.
The company is incorporated in the State of Delaware while having product and business development and operations in both the US and Asian countries.Learn more about Celgenyx
The Company’s strategy is to leverage innovations and cutting-edge technologies in the US, and large patient population, favorable regulatory policies for translational clinical trials, and fast growing market opportunities in Asia, particularly in greater China, for cost-effective product development and expedited market entry for global markets.
Through strategic partnerships, the Company is building a value-added, cost-effective, and timely-efficient chain for IND-enabling studies, GMP manufacturing, regulatory fillings, and clinical trials for the development of cell and gene therapies.Learn More